Percheron Therapeutics Limited has released a press release.
Placement to Accelerate Development of ATL1102 in DMD
Filed with ASX ·
6ix hasn’t read this filing yet.
Percheron Therapeutics Limited on 6ix
Earlier from Percheron Therapeutics
- Pause in trading
- Response to ASX Price and Volume Query
- Full Year Statutory Accounts
- First Patient Dosed in Phase II DMD Clinical Trial
- ANP initiates ATL1102 Phase II clinical trial in DMD
Later from Percheron Therapeutics
- Phase II clinical trial in DMD Update
- Phase II clinical trial in DMD Fully Enrolled
- Phase II DMD clinical trial on track for dosing completion
- Acromegaly Early Access Program Status Update
- ATL1102 for DMD European regulatory interactions
Follow Percheron Therapeutics into a list and get an email when it puts out news.
Follow Percheron Therapeutics